December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

4.030 +0.080 (+2.03%)
Delayed Quote Updated: 10:31 AM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
News headline image
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution,... 
From Jaguar Health, Inc.
Via ACCESS Newswire
Gapping stocks in Friday's session ↗
Via Chartmill
Unusual volume stocks in Thursday's session ↗
Via Chartmill
The market is filled with gapping stocks in Thursday's session. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Wednesday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
News headline image
Jaguar Health Receives Fee Waivers from FDA
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution,... 
From Jaguar Health, Inc.
Via ACCESS Newswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
News headline image
Jaguar Health, Inc. Announces Reverse Stock Split
Reverse split approved at April 2026 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on September 17, 2026 
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Continuation of treatment with blinded doses of crofelemer in the extension phase of the trial will support company's plans to file an NDA in mid-2027 for MVID, an ultrarare pediatric disease 
From Jaguar Health, Inc.
Via ACCESS Newswire
Top movers analysis one hour before the close of the markets on 2026-09-08: top gainers and losers in today's session. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2026-09-08: top gainers and losers in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Neonorm ® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI... 
From Jaguar Health, Inc.
Via ACCESS Newswire
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including... 
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Intelligent Bio Solutions (NASDAQ:INBS) stock moved upwards by 8.2% to $2.63 during Tuesday's after-market session. The company's market cap stands at $7.2 million. Jaguar Health (NASDAQ:JAGX)... 
Via Benzinga
News headline image
Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Jaguar Health Reports Q2 2026 Results: Full Earnings Call Transcript ↗
Jaguar Health (NASDAQ:JAGX) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings... 
Via Benzinga
Topics Earnings
News headline image
Jaguar Health Reports Second Quarter 2026 Financials
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
From Jaguar Health, Inc.
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.